These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 9504550)
41. [Current role of intracavernous therapy in the treatment of erectile dysfunction]. Asuar Aydillo S Arch Esp Urol; 2002 Jun; 55(5):475-82. PubMed ID: 12174413 [No Abstract] [Full Text] [Related]
42. Factors in predicting initial in-office therapeutic dosages of alprostadil for the treatment of organic impotence. Intili H Urol Nurs; 1998 Jun; 18(2):111-3. PubMed ID: 9866639 [TBL] [Abstract][Full Text] [Related]
43. Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction. Meinhardt W; de la Fuente RB; Lycklama à Nijeholt AA; Vermeij P; Zwartendijk J Int J Impot Res; 1996 Mar; 8(1):5-7. PubMed ID: 8735187 [TBL] [Abstract][Full Text] [Related]
44. Clinical experience with intraurethral alprostadil (MUSE) in the treatment of men with erectile dysfunction. A retrospective study. Medicated urethral system for erection. Guay AT; Perez JB; Velásquez E; Newton RA; Jacobson JP Eur Urol; 2000 Dec; 38(6):671-6. PubMed ID: 11111182 [TBL] [Abstract][Full Text] [Related]
45. Intracavernous injection of alprostadil for erectile dysfunction. Med Lett Drugs Ther; 1995 Sep; 37(958):83-4. PubMed ID: 7674992 [No Abstract] [Full Text] [Related]
48. The role of intracavernosal vasoactive agents to overcome impotence due to spinal cord injury. Earle CM; Keogh EJ; Ker JK; Cherry DJ; Tulloch AG; Lord DJ Paraplegia; 1992 Apr; 30(4):273-6. PubMed ID: 1625897 [TBL] [Abstract][Full Text] [Related]
49. Intracavernous Injections in Spinal Cord Injured Men With Erectile Dysfunction, a Systematic Review and Meta-Analysis. Chochina L; Naudet F; Chéhensse C; Manunta A; Damphousse M; Bonan I; Giuliano F Sex Med Rev; 2016 Jul; 4(3):257-269. PubMed ID: 27871959 [TBL] [Abstract][Full Text] [Related]
50. Medical treatment of erectile dysfunction. Burns-Cox N; Gingell C Postgrad Med J; 1998 Jun; 74(872):336-42. PubMed ID: 9799886 [TBL] [Abstract][Full Text] [Related]
52. Erectile response to transurethral alprostadil, prazosin and alprostadil-prazosin combinations. Peterson CA; Bennett AH; Hellstrom WJ; Kaiser FE; Morley JE; Nemo KJ; Padma-Nathan H; Place VA; Prendergast JJ; Tam PY; Tanagho EA; Todd LK; Varady JC; Gesundheit N J Urol; 1998 May; 159(5):1523-7; discussion 1527-8. PubMed ID: 9554347 [TBL] [Abstract][Full Text] [Related]
53. An international comparison of the reliability and responsiveness of the Duke Health Profile for measuring health-related quality of life of patients treated with alprostadil for erectile dysfunction. Parkerson GR; Willke RJ; Hays RD Med Care; 1999 Jan; 37(1):56-67. PubMed ID: 10413393 [TBL] [Abstract][Full Text] [Related]
54. [The opinion of patients treated with intracavernous injections: the EASY survey]. Desvaux P; Alexandre B Presse Med; 2005 Jul; 34(13 Suppl):10-2. PubMed ID: 16158022 [TBL] [Abstract][Full Text] [Related]
55. Safety and efficacy of alprostadil sterile powder (S. Po., CAVERJECT) in diabetic patients with erectile dysfunction. Tsai YS; Lin JS; Lin YM Eur Urol; 2000 Aug; 38(2):177-83. PubMed ID: 10895010 [TBL] [Abstract][Full Text] [Related]
56. Use of medications for erectile dysfunction in the United States, 1996 through 2001. Wysowski DK; Swann J J Urol; 2003 Mar; 169(3):1040-2. PubMed ID: 12576841 [TBL] [Abstract][Full Text] [Related]